Today: 9 June 2026
Browse Category

NYSE:TEVA 1 November 2025 - 29 April 2026

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
29 April 2026
··
Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva shares rose about 4% to $33.29 after announcing a funding deal with Royalty Pharma worth up to $500 million for its experimental vitiligo drug. An SEC filing previewed Teva’s 2025 outlook, including projected revenue of $16.8–$17.0 billion and adjusted EBITDA of $4.8–$5.0 billion. Investors await more details at Tuesday’s J.P. Morgan Healthcare Conference.
12 January 2026
··
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.
24 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva shares traded near $29, close to 52-week highs, after filing a new FDA application for a once-monthly schizophrenia drug and receiving analyst upgrades. Market cap stands at about $32–33 billion. The company reported improved debt ratios and expects consensus 2025 EPS of $2.70. Technical indicators show the stock as overbought but still in an uptrend.
10 December 2025
··
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Pharmaceutical reported Q3 2025 adjusted EPS of $0.78 on $4.48 billion revenue, beating estimates and sending shares up 10–11% to a new 52-week high. The company raised 2025 guidance, citing strong sales of Austedo and other branded drugs, and Fitch upgraded its credit rating in May. Debt fell to $16.79 billion. Teva’s forward P/E remains below industry averages despite the stock’s sharp recovery.
5 November 2025
···
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 01.11.2025

WTI and RBOB futures rose Friday as traders weighed possible U.S. strikes on Venezuela, Russian energy sanctions, and OPEC+ production plans. Gains were limited by a stronger dollar and weak China PMI. Teva shares jumped 8.1% last week amid DCF-based undervaluation signals. MKS Instruments closed at $143.71, near its estimated fair value, after a 53% three-month rally.
1 November 2025
··

Stock Market Today

  • China Plans $295 Billion AI Data Center Network Amid Global Tech Stocks Drop
    June 9, 2026, 2:46 PM EDT. China is reportedly planning to invest around $295 billion over five years to establish a nationwide data center network dedicated to AI, aiming to reduce reliance on US technology by prioritizing domestic suppliers like Huawei. The initiative involves state-owned telecoms managing the infrastructure and seeks to unify fragmented data centers into a national system by 2028. This comes as chip stocks and major tech shares plunged, dragging down the Nasdaq and S&P 500 indexes. China's AI sector now includes over 6,200 companies with a market worth $177 billion. The plan may be funded through sovereign debt and state-backed funds, highlighting Beijing's strategic commitment to AI infrastructure despite slower economic growth.

Latest articles

Vanguard’s $1 Trillion VOO ETF Draws Investor Questions About the Road Ahead

Vanguard’s $1 Trillion VOO ETF Draws Investor Questions About the Road Ahead

9 June 2026
Vanguard’s S&P 500 ETF (VOO) became the first ETF to surpass $1 trillion in assets, drawing renewed scrutiny to low fees, index concentration, and valuation risks as tech stocks slid and VOO fell about 1% Tuesday, highlighting investor debate over sticking with S&P 500 trackers or shifting to broader funds like VTI.
AI chip ETF bulls hit with more losses as leveraged funds slide

AI chip ETF bulls hit with more losses as leveraged funds slide

9 June 2026
SOXL plunged 15.4% as leveraged semiconductor funds led tech’s sharp selloff, testing the narrow AI trade behind this year’s market gains; major chip stocks like AMD and Broadcom also tumbled, with investors eyeing Wednesday’s CPI data and the upcoming SpaceX listing as key risks for further volatility.
Bitcoin Hovers at $61,000 With CPI Report in Focus for Crypto Traders

Bitcoin Hovers at $61,000 With CPI Report in Focus for Crypto Traders

9 June 2026
Bitcoin slid to near $61,000, down 3%, as traders cut risk ahead of Wednesday’s U.S. inflation report, which is expected to show May CPI up 4.2% year-on-year—well above the Fed’s 2% target—keeping rate-hike risk in play and pressuring crypto and related stocks, with $5.8 billion in digital asset outflows reported in recent weeks.
Go toTop